Home Blog Page 1309

Moomoo Named TradingView’s Best Broker for Stocks in North America, Earns Top ETF Honors from BrokerChooser

By
Advertorial Desk
-

Global investment platform recognized by TradingView and BrokerChooser for stock breadth, ETF access, and investor experience

JERSEY CITY, N.J., Feb. 9, 2026 /PRNewswire/ — Moomoo, a leading investment and trading platform, today announced it has been named Best Broker for Stocks in North America by TradingView as part of its 2025 Broker Awards, while also earning top honors from BrokerChooser, including Best ETF Broker and Best Broker for Investing in Gold ETFs. [1] The platform also secured positions among the top five brokers for margin trading and cash interest services selected by BrokerChooser.


TradingView Awards Moomoo Best Broker for Stocks in North America

TradingView’s Broker Awards spotlight platforms that deliver exceptional trading experiences to its global community of investors and traders. The Best in Stocks – North America recognition highlights brokers offering extensive access to local and international equities, enabling traders to explore opportunities across global markets with depth, transparency, and advanced tools.

“We are pleased to recognize moomoo with the Best Stock Broker Award in North America for providing varied trading offerings including U.S. stocks in the U.S. and ASEAN markets, supported by service excellence and strong user trust. Their commitment to quality and reliability distinguishes them in the industry,” said Rauan Khassan, Chief Growth Officer at TradingView.

BrokerChooser Names Moomoo Best ETF Broker and Best Broker for Investing in Gold ETFs

In addition to the TradingView award, moomoo was recognized by BrokerChooser, an independent online broker comparison platform that reviews top-tier regulated investment service providers worldwide. For the 2026 awards, BrokerChooser assessed over 100 brokers across more than 1,200 distinct metrics using a refined methodology that accounts for emerging trends in investor behavior and evolving market demands.

Moomoo achieved an outstanding 4.9 out of 5 rating in both the ETF and Gold ETF categories. BrokerChooser specifically recommends Moomoo for investors and traders seeking zero-commission trading with a focus on U.S. markets, highlighting the platform’s combination of:

“After comprehensive testing, we found that moomoo is the best choice for retail investors who want diversification across multiple asset classes via ETFs — one of the most cost-effective ways to participate in the market. Competition among brokers is getting stronger, but moomoo stood out not only for its strong overall conditions, no inactivity penalties for long-term investors, and access to a wide range of US ETFs, but also for its excellent mobile platform. It strikes a great balance between ease of use and putting the right information in users’ hands,” said Balázs Faluvégi, Senior Analyst at BrokerChooser.

“Being recognized by TradingView as the Best Broker for Stocks in North America and earning top honors from BrokerChooser for our ETF offerings is especially meaningful because it reflects how real investors engage with our platform day to day,” said Neil McDonald, CEO of moomoo U.S. “These awards from two highly respected industry leaders reinforce our commitment to delivering deep market access, powerful tools, and a modern investing experience built for today’s global retail investor.”

  1. Accolades are not indicative of future performance. Moomoo Financial Inc. is not affiliated with Broker Chooser or TradingView. For additional information, please visit: https://brokerchooser.com/best-brokers, and and https://www.tradingview.com/blog/en/broker-awards-2025-winners-56493/
  2. $0 commission trading is available only to U.S. residents trading in the U.S. markets through Moomoo Financial Inc. Other fees may apply. For more info, visit moomoo.com/us/pricing.
  3. The Cash Sweep Program is a feature of the brokerage account and should not be viewed as a long-term investment or savings option. The APY might change at any time. For information about the Moomoo Cash Sweep Program, please see www.moomoo.com/us/sAupport/topic4_222 for details of how the program works. Neither Moomoo Financial Inc. nor any of its affiliates are banks.

*Investing involves risk and the potential to lose principal. Securities offered through Moomoo Financial Inc., Member FINRA/SIPC.

About Moomoo

Moomoo is a leading global investment and trading platform dedicated to empowering investors with user-friendly tools, data, and insights. Our platform is designed to provide essential information and technology, enabling users to make well-informed investment decisions. With advanced charting tools, pro-level analytical features, moomoo evolves alongside our users, fostering a dynamic community where investors can share, learn, and grow together.

Founded in the US, moomoo has expanded its global presence to serve investors across multiple markets, including Singapore, Australia, Japan, Canada, Malaysia, and New Zealand. As a subsidiary of a Nasdaq-listed company, moomoo is trusted by more than 28 million investors worldwide and has earned recognition from leading financial institutions and publications for its innovation and reliability.

For more information, please visit moomoo’s official website at www.moomoo.com or feel free to email us: pr@us.moomoo.com.

YY Group Holding Announces Total Assets and Net Assets per Share of $1.11 and $0.63, Respectively, as of June 30, 2025

By
Advertorial Desk
-

Unaudited Financials Reflect $44.0M in Total Assets and $24.9M in Net Assets

SINGAPORE, Feb. 9, 2026 /PRNewswire/ — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group” or the “Company”), a global leader in on-demand workforce solutions and integrated facilities management (IFM), today announced that, as of June 30, 2025, its unaudited total assets of approximately $44.0 million equated to approximately $1.11 per share of common stock, and its net assets of approximately $24.9 million equated to approximately $0.63 per share.

These estimates reflect preliminary financial data derived from management’s period-end closing process as of June 30, 2025. During the period, YY Group continued to execute its growth strategy by broadening its IFM service portfolio through strategic acquisitions and expanding its operational footprint across the casual labor markets within the hospitality and facility services sectors.

These estimates have not been reviewed or audited by the Company’s independent registered public accounting firm and are subject to normal closing adjustments and review procedures. The Company is providing this information to offer additional transparency regarding its financial position and capital base following a period of strategic growth. These metrics reflect the Company’s focus on maintaining a robust balance sheet while scaling its integrated service ecosystem across global markets.

“The disclosure of our total assets and net asset value per share provides stockholders with a clearer picture of the Company’s fundamental strength,” stated Mike Fu, Chief Executive Officer of YY Group Holding Limited. “These figures highlight the solid financial foundation we have established as we continue to scale our operations and drive long-term value for our stockholders.”

About YY Group Holding Limited
YY Group Holding Limited (Nasdaq: YYGH) is a Singapore-headquartered, technology-enabled platform providing flexible, scalable workforce solutions and integrated facility management (IFM) services across Asia and beyond. The Group operates through two core verticals: on-demand staffing and IFM, delivering agile, reliable support to industries such as hospitality, logistics, retail, and healthcare.

Leveraging proprietary digital platforms and IoT-driven systems, YY Group enables clients to meet fluctuating labor demands and maintain high-performance environments. In addition to its core operations in Singapore and Malaysia, the Group maintains a growing presence in Asia, Europe, Africa, Oceania and the Middle East.

Listed on the Nasdaq Capital Market, YY Group is committed to service excellence, operational innovation, and long-term value creation for clients and shareholders.

For more information on the Company, please visit https://yygroupholding.com/.

Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the YY Group Holding Limited’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) growth of the hospitality market (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and YY Group Holding Limited undertakes no duty to update such information, except as required under applicable law.

Investor Contact
Jason Phua Zhi Yong, Chief Financial Officer
YY Group
enquiries@yygroupholding.com

Blue Ocean Technologies Announces Executive Changes

By
Advertorial Desk
-

Appoints Robert Virgilio as Chief Compliance Officer of Blue Ocean ATS & Expands South Korean Team with Addition of Daehyun Kim in new Trade Support Role

NEW YORK, Feb. 9, 2026 /PRNewswire/ — Blue Ocean Technologies, LLC, a capital markets fintech leader in global trading and data, announced today the appointment of Robert Virgilio as Chief Compliance Officer of Blue Ocean ATS, who will be based in New York. The Company also announced the appointment of Daehyum (Derek) Kim as a Trade Support Senior Analyst, a newly created position to support continued growth in South Korea and throughout Asia Pacific. Based in Blue Ocean’s Seoul office, Kim will contribute to Operations teams’ overnight support in the region.

Brian Hyndman, CEO of Blue Ocean Technologies commented, “We are excited about the appointment of our Chief Compliance Officer and the expansion of our team in Seoul as we continue our geographical growth and our critical role within the US financial markets. Robert brings a wealth of trading, compliance and regulatory experience given his background leading complex regulatory projects and will be an asset to Blue Ocean’s compliance framework as we expand overnight US equity trading for global investors. Derek is adding a much-needed resource to our Asia-Pacific operations given our rapid growth and the return of the Korean subscribers with his deep expertise in equities and overnight trading infrastructure.”

Virgilio brings over 25 years of experience managing all aspects of compliance for global financial services organizations, with deep expertise in evolving market and regulatory structures, US and non-US institutional trading, electronic and algorithmic trading, and supervisory controls for broker-dealers. He served in compliance leadership positions at ICBC Financial Services, KPMG LLP’s Advisory division, BNY ConvergEx, Cowen and Company/SG Cowen, Nikko Securities and the New York Stock Exchange.

Most recently Kim was at Daishin Securities, where he led Global Investment Products, spearheading retail sales for global equity exchange trading and brokerage, managing relationships with NYSE, Nasdaq, and intermediate brokers, and developing ATS connectivity while working alongside IT teams. He also operated a 24-hour trading desk with the global derivatives team, handled order execution and risk management for financial/commodities derivatives, and collaborated with FCMs and exchanges like CME, ICE, SGX, and HKEX.

Virgilio holds a Bachelor of Science from Niagara University, an MBA from St. John’s University, and FINRA Series 4, 7, 9/10, 14, 24, and 57 licenses. He is a past member of the SIFMA Self-Regulation and Supervisory Practices Committee, and NYSE Market Compliance Advisory Committee. Kim holds a Master of Commerce (Finance) from the University of Sydney and a Bachelor’s/Diploma in Information Technology from Queensland University of Technology. He is a Certified Securities and Derivatives Investment Advisor (Korea Financial Investment Association).

About Blue Ocean Technologies:
Blue Ocean Technologies, LLC (BOT) is a unique capital markets fintech company empowering global investors by making trading possible during US overnight trading hours. Blue Ocean ATS, LLC, and its trading system Blue Ocean Alternative Trading System (BOATS), currently trade US National Market System (NMS) stocks from 8:00 pm to 4:00 am ET from Sunday – Thursday. Founded in 2019, Blue Ocean ATS is on a mission to transform US trading to Global trading via its flagship service, Blue Ocean Session, providing access and transparency to subscribers in all time zones during non-traditional US market hours. For more information, visit www.blueocean-tech.io. Contact us at sales@blueoceanats.com.

Media Contact:
press@blueocean-tech.io 

Voicecomm Technology Wins 300 million RMB Major “AI+ Elderly Care” Project Forging a New Engine for the Silver Economy

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – Voicecomm Technology Co., Ltd. (“Voicecomm Technology” or the “Company”, Stock Code: 2495.HK), one of the leading enterprises in Conversational Artificial Intelligence (CoAI), is pleased to announce that it has successfully won the bid for the “South Sichuan Intelligent Valley AI Vertical Large Model Innovation Platform (川南智谷人工智能垂直大模型創新平台)- Silver Economy Construction and Operation Project” in Neijiang City, Sichuan Province. The total contract value is close to 300 million RMB, including approximately RMB 150 million for the initial platform construction costs; and approximately RMB 140 million for medium- to long-term project operation costs. This indicates that Voicecomm Technology has successfully established a full-stack service closed loop of “construction + operation”. This project marks a significant breakthrough for the Company in pioneering the new strategic track of “AI + healthcare” and represents its first replicable city-level smart elderly care benchmark project.

According to report from iResearch, as the end of 2024, China’s population aged 60 and above has exceeded 310 million, accounting for 22.0% of the total population. As the first city-level AI elderly care project, this not only affirms Voicecomm Technology’s position in the “AI + Elderly Care” sector but also signals a new trend in government investment towards smart elderly care—shifting from infrastructure construction to pursuing effective operational services.

Mr. Sun Qi, Founder and Executive Director of Voicecomm Technology Co., Ltd., said: “China is accelerating into a phase of deep aging, and the needs of hundreds of millions of elderly people constitute a vast blue ocean. Faced with the challenges of an aging society today, we aim to leverage artificial intelligence technology to explore a new, scientifically-driven path for elderly care. The Neijiang project is our first demonstration project in the healthcare sector. Its core lies not in stacking hardware but in using AI as the engine to make elderly care services truly intelligent and smooth, thereby enhancing the quality of life and dignity of the elderly. We hope to build this project into a replicable model for more cities to learn from.”

This project is expected to become a powerful engine for activating the silver economy in Neijiang City. Guided by national Smart Elderly Care policies, the project is anticipated to drive an annual output value exceeding 1 billion RMB in the local elderly care service industry and create a large number of job opportunities. By establishing a unified smart health and elderly care service platform, the project will strive to build a “15-minute elderly care service circle,” achieving deep integration between technology and people’s livelihoods.

Since its establishment in 2005, Voicecomm Technology has been committed to the research and application of Conversational Artificial Intelligence and unified communications technologies. Its solutions cover multiple scenarios in fields such as city management and administration, automotive and transportation, telecommunications, finance, healthcare, and energy management. This successful bid once again unveils Voicecomm Technology’s commitment to promoting technological progress and social development.

Hashtag: #Voicecomm

The issuer is solely responsible for the content of this announcement.

Voicecomm Technology Co., Ltd.

Founded in 2005 and headquartered in Wuhan, Voicecomm Technology is one of the leading enterprises in the field of Conversational Artificial Intelligence (CoAI) listed on the Main Board of the Hong Kong Stock Exchange, and obtained the qualification as National-level “Little Giant” Enterprise and High-Tech Enterprise. Leveraging advanced unified communication technologies, core conversational AI technologies and self-developed product engines, we are capable of addressing diverse enterprise demand across “collaborative communication”, “intelligent decision-making”, and “efficient execution”, delivering a one-stop enterprise level intelligent interaction experience. Our solutions have been widely adopted in key industries including city management and administration, automotive and transportation, telecommunications, finance, healthcare, and energy management, empowering clients in digital transformation and business innovation.

Pacific Century Premium Developments Limited announces annual results for the financial year ended December 31, 2025

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 9 February 2026

2025 Annual Results – Financial Highlights

(Figures for the corresponding period in 2024 are shown in brackets)

  • Consolidated revenue: HK$1,046million (HK$695million)
  • Consolidated net loss attributable to equity holders of the Company:
    HK$    69 million (HK$230million)
  • Basic loss per share: 3.38 HK cents (11.29 HK cents)
  • No final dividend (No final dividend)

Pacific Century Premium Developments Limited (“PCPD”, SEHK: 00432) has announced its annual results for the year ended December 31, 2025.

The consolidated revenue of PCPD and its subsidiaries (together, the “Group”) amounted to HK$ 1,046 million, representing an increase of 51% compared to the revenue of HK$ 695 million in 2024.

The consolidated net loss attributable to equity holders of the Company for the year of 2025 was HK$ 69 million, compared to the net loss of HK$ 230 million in 2024.

Basic loss per share for 2025 was 3.38 Hong Kong cents compared to the loss per share of 11.29 Hong Kong cents for the previous year.

The Board of Directors has not recommended the payment of a final dividend for the year ended December 31, 2025.

In 2025, PCPD achieved robust full-year results, driven by the sustained surge in international travel across our key Asian markets, our operational strengths, and the continued recognition of our high-quality portfolio. This performance was underpinned predominantly by contributions from two segments: Park Hyatt Niseko, Hanazono, our hospitality business in Hokkaido, which delivered a notable rise in occupancy and revenue, and our ski and recreation operations in Niseko, Hokkaido, which also saw a surge in demand and revenue.

Park Hyatt Niseko, Hanazono, our hotel operations in Hokkaido, delivered a robust performance in 2025, as the boom in Japan‘s tourism sector continued throughout the year, again with record-breaking tourist arrivals. The average occupancy rate of Park Hyatt Niseko increased by 4 percentage points.

During the winter season of 2024/2025, total ski-lift and gondola rides increased 9% year-on-year. The travel surge continued to drive robust demand for our recreational business in Niseko well beyond the cold months.

In Phang Nga, Thailand, the Group has sold or reserved 40% of Phase 1A villas. The Group’s revenue from its property development in Thailand totalled HK$14 million for the year ended December 31, 2025, compared to no revenue in 2024.

We formed a strategic alliance with Hotel Properties Limited in Singapore to bring a Four Seasons Resort and Branded Residences to the prestigious integrated resort community of Aquella in Phang Nga. The move represents a significant milestone in PCPD‘s long-term vision of transforming Aquella into a visionary integrated resort destination that effortlessly blends luxury living, recreation and exceptional service.

In Jakarta, Indonesia, the occupancy of our premium commercial building, Pacific Century Place, Jakarta (“PCP Jakarta”), was stable throughout the year, and the project remained a consistent revenue contributor to the Group. As of December 31, 2025, the office space committed occupancy was 87%, compared to 85% in the previous year.

Development of the superstructure of the Group‘s project at 3–6 Glenealy, Central, Hong Kong, has been progressing well. We have reached a key structural milestone, with the superstructural work now completed and installation of the curtain walls progressing at pace. The name of the development has also been unveiled as “Central Residence by the Park”, and its completion is scheduled for the first half of 2026.

In the long run, we remain cautiously optimistic about the long-term outlook for property sectors in Hong Kong, Japan, Thailand and Indonesia. With PCPD‘s disciplined execution and proactive risk management, we have confidence in our ability to drive continued growth and deliver sustained value.

Mr. Benjamin Lam, PCPD’s Deputy Chairman and Group Managing Director, said: “We will maintain our prudent yet proactive approach, allocating resources carefully and pursuing value-enhancing initiatives. Our priority remains to drive sustainable growth, improve profitability, and deliver solid returns to shareholders and stakeholders.”

Hashtag: #PacificCenturyPremiumDevelopments

The issuer is solely responsible for the content of this announcement.

About PCPD

Pacific Century Premium Developments Limited (“PCPD” or the “Group”, SEHK: 00432) is principally engaged in the development and management of premium-grade property and infrastructure projects as well as premium-grade property investments. PCCW Limited (“PCCW”, SEHK: 00008) is the single largest shareholder of the Group.

Global e∙dentity™ Announces End of Conditional Licensing Agreement with FDI Advisory Group

By
Advertorial Desk
-

CUPERTINO, Calif., Feb. 9, 2026 /PRNewswire/ — Global e∙dentity™, a Delaware corporation and leading innovator in multi-factor biometric identity IP-based solutions, today announced that it has ended its November 2025 conditional exclusive global banking licensing and sales agreement that it had granted to FDI Advisory Group (www.fdiadvisorygroup.com) for mobile banking applications, effective January 30, 2026. No details regarding the termination will be disclosed. Any and all affected customers have been notified of the matter.

Global e∙dentity™ remains committed to advancing its patented quantum-resilient vein biometric technologies and is actively pursuing new strategic opportunities to deliver secure, living identity solutions to the global banking and airport sectors.

About Global e∙dentity™ 

Global e∙dentity™ Inc. is a registered corporation in Delaware and a leading provider of multi-factor biometrics, digital identity solutions, and Airport biometrics. For more information, please visit www.globaledentity.com. Global e∙dentity™ and its product(s) are either registered trademarks or trademarks of Global e∙dentity™ Inc. in the United States and/or other countries.

Global e∙dentity™ Corporate Communications 

Sophia Miller 

Email: somiller@globaledentity.com

DIFF Biotech’s Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway

By
Advertorial Desk
-

HANGZHOU, China, Feb. 9, 2026 /PRNewswire/ — Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval as a Class 1.2 innovative vaccine from China’s National Medical Products Administration (NMPA).

As the first domestically self-developed nasal spray influenza vaccine in China to advance into clinical trial, DIFF-flu leverages a pioneering M2 gene–modified attenuation technology, protected by multiple international invention patents. This achievement underscores DIFF Biotech’s leading capabilities in respiratory infectious disease prevention and establishes an important foundation for future industrialization.

Dr. Jiasheng Song, Chief Executive Officer of DIFF Biotech, commented: “DIFF-flu’s clinical approval marks a major milestone for DIFF Biotech and a meaningful achievement for independent innovation in respiratory infectious disease prevention. As a next-generation attenuation platform, DIFF-flu is designed to achieve an optimal balance between immunogenicity and safety—an advance that holds significant potential for improving influenza protection. We believe this progress will help expand access to safer, more effective influenza prevention, particularly for older adults and other vulnerable populations. DIFF Biotech will continue to drive next-generation vaccine innovation to strengthen public health and contribute to global biomedical progress.”

A New Attenuation Strategy: Replication Restriction for Enhanced Safety

DIFF-flu is developed using an innovative M2 gene–modification strategy that produces a replication-restricted vaccine strain. This approach achieves a deliberate balance between robust attenuation and strong immunogenicity—generating a potent immune response while maintaining an exceptional safety profile. In essence, the technology places a “safety harness” on the virus to prevent uncontrolled replication.

Existing nasal spray influenza vaccines on the market rely on cold-adapted attenuation, allowing the vaccine virus to replicate efficiently only at lower temperatures such as those in the nasal cavity but limiting replication in the warmer lower respiratory system and lungs. Because these strains can still replicate in nasal mucosa and cause mild viral shedding, they are generally not recommended for older adults or immunocompromised individuals.

Preclinical data indicate that DIFF-flu offers a differentiated safety profile, with negligible viral shedding, and significantly reduced viral loads in respiratory tissues, suggesting the potential to extend nasal spray vaccine eligibility to older adults and other underserved groups.

Notably, preclinical data show that DIFF-flu confers 100% protection against epidemic strains circulating more than 50 years ago, while also eliciting strong immunity against contemporary variants.

Market Landscape: At-Home Use Policies Unlock Global Opportunities

The global influenza vaccine market is undergoing a period of structural evolution. While injectable vaccines remain the predominant format, they continue to face long-standing challenges such as suboptimal uptake and limited ability to curb viral transmission. Nasal spray vaccines—which induce mucosal immunity directly at the site of viral entry—represent an increasingly important direction for influenza prevention.

In September 2024, the U.S. FDA granted authorization for at-home administration of a related nasal spray influenza vaccine, paving the way for direct-to-consumer (DTC) distribution models. This regulatory milestone significantly improves convenience and accessibility for the public and creates favorable conditions for DIFF-flu’s future global introduction.

Global Influenza Burden Underscores the Need to Strengthen Herd Immunity

According to the World Health Organization (WHO), seasonal influenza infects up to 1 billion people each year, causing 3–5 million severe cases and 290,000–650,000 respiratory deaths globally.

Older adults account for the majority of influenza-related deaths and face heightened risks of complications such as pneumonia, myocarditis, encephalitis, and acute cardiorespiratory failure. Studies show that influenza vaccination can reduce hospitalization risk by 40–60%, making improved vaccine coverage especially critical for aging and medically vulnerable populations.

Despite this, vaccination rates remain low in many parts of the world. In China, influenza vaccination coverage is approximately 3.8%, far below mature markets such as the United States (around 49.3%). Increasing vaccination uptake is essential to protect high-risk groups and strengthen community-level immunity.

About DIFF Biotech

Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) is a clinical-stage biotechnology company specializing in its proprietary Viraltech Architect Platform. Leveraging this platform, the company has built an integrated, end-to-end capability for the development of differentiated biologics. DIFF Biotech has filed over 70 domestic and international invention patents, including more than 10 PCT applications, and has received multiple honors such as the 23rd China Excellent Patent Award, “High-tech Enterprise” and “Quasi-Unicorn” enterprise.

The company’s R&D efforts span mucosal vaccines, antiviral drugs, oncolytic viruses, and gene therapy products. Its vaccine pipeline—powered by proprietary attenuation technologies—effectively establishes the body’s first line of defense at the mucosal barrier, offering clear competitive differentiation. In the oncolytic virus and gene therapy domains, DIFF Biotech has built distinctive capabilities in vector targeting, controllable replication, and high-efficiency gene delivery, enabling the development of advanced, next-generation biologics.

 For more information, please visit https://en.diff-biotech.com/.

E-mail: BD@diff-biotech.com 

 

BioDlink Recognized by Client for Enabling the World’s First Dual-Payload ADC to Enter Clinical Trials

By
Advertorial Desk
-
  • BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development.
  • BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution.

SUZHOU, China, Feb. 9, 2026 /PRNewswire/ — BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group (“Kanghong Pharmaceutical”), recognizing BioDlink’s critical contribution to the successful clinical approval of KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development.

KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia’s Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025.

As Kanghong Pharmaceutical’s CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation, and formulation research.

Efficient Execution of a Complex First-in-Class Program

KH815 required advanced process design and analytical control, including precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization. Leveraging its expertise in complex ADC development, BioDlink delivered a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines.

Despite the complexity of conjugation process development and analytical characterization, BioDlink applied strong technical expertise to define and lock robust process and analytical strategies, enabling successful scale-up and batch release. Through continuous process optimization, development, manufacturing, and regulatory submission activities were completed 1.5 months ahead of plan, exceeding client expectations and demonstrating strong execution capability, which earned high recognition from Kanghong Pharmaceutical for BioDlink’s technical expertise and service excellence.

Advancing Innovation in ADC Development

The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink remains committed to providing end-to-end CDMO services to global partners, accelerating the development of complex biologics from early development through commercialization.

About Kanghong Pharmaceutical
Kanghong is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, neuropsychiatric and others.

Kanghong is devoted to the lives of patients through high quality, innovation and responsibility. Since its establishment, the company keeps researching, producing, and commercializing safer and more efficient drugs for pressing unmet medical needs.

The company’s purpose is to fundamentally improve patients’ physical ability and social medical efficacy by using innovative science and breakthrough treatments to achieve  progress in human health.

About BioDlink
BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing.

With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs.

The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivian.

Guided by the philosophy of “Quality First, Innovation Driven, Success Together”, BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: https://biodlink.com/ 

1...1,3081,3091,310...6,715Page 1,309 of 6,715